Join Samuel lab
Whether you want to research, invest, donate or partner with us to accelerate our life-changing discoveries, we'd be delighted to hear from you. We have opportunities for PhD students, post docs and senior researchers to join our lab. Feel free to contact Professor Chrishan Samuel with any queries.
We aim to develop and evaluate new therapies and combination strategies, and identify common vs organ-specific targets, for treating the fibrosis (scarring) that is a hallmark of various cardiac, renal and airway/lung diseases.
Previously (2005-2014), I consulted to and conducted sponsored research for BAS Medical/Corthera Inc (USA) and Novartis AG (Switzerland), which led to clinical evaluation of recombinant human relaxin for promoting tooth remodelling (PMID: 22284287) and treating acute heart failure (PMID: 23141816, 28452195).
I also engaged with Compugen (Israel; 2009-2010) to characterise a novel anti-fibrotic GPCR-agonist, CGEN25009; and with Imago Pharmaceuticals (USA) to evaluate their novel JNK inhibitors as treatments for renal fibrosis.
Currently, I consult to and am working with:
- Relaxera Pharmazeutische Gesellschaft mbH & Co. KG (Germany) – Combining recombinant human relaxin with ACE inhibitors in models of heart failure;
- Merck & Co (USA) – Novel relaxin-like peptides;
- Cynata Therapeutics Ltd (Australia) – CymerusTM iPSC-derived MSCs as a treatment for asthma;
- AusBio Ltd (Australia) – Novel glycoproteins as treatments for chronic obstructive pulmonary disease.
Peter Kerr (Director of Nephrology at Monash Medical Centre) – Endothelial progenitor cell function in patients with end-stage kidney disease.
Testimonials"Prof Chrishan Samuel has been instrumental in establishing a research-industry partnership between Cynata Therapeutics and Monash University, which has been highly productive and beneficial for both parties. As Chief Investigator, he and Dr Simon Royce initiated meetings with Cynata in 2016, which led to evaluation of Cynata’s CymerusTM iPSCs-derived MSCs in an experimental model of chronic allergic airways disease/asthma. It was clear from their track records that they are amongst the foremost setups for drug testing in chronic disease animal models available in Australia. We were impressed by their capabilities outlined on the website and research project contracts were drawn up subsequently for an initial program. Following the successful execution of this project across all the preclinical endpoints two additional projects were established and completed. The possibility of conducting a clinical trial of Cynata’s Cymerus™ iPSC-derived MSCs in this therapeutic area is now being explored, on the basis of the results of the preclinical studies conducted by Prof Samuel’s group."
Dr. Kilian Kelly
Vice President, Product Development
Cynata Therapeutics Limited
Donate to our lab
We welcome donations for any aspects of our work that donors feel compelled to contribute to, towards developing novel therapies/strategies for treating various cardiovascular, renal and airway/lung diseases. These diseases collectively contribute to significant morbidity and mortality in Australia and worldwide, and our work is attempting to save the healthcare system from billions of dollars in dialysis and organ replacement therapy.
Selected funding groups
We gratefully acknowledge the funding given to our lab by:
- Commercial Sources
Teaching activities (Annual lectures/activities)
BMS5006: Co-ordinate Theme 1: Atherosclerosis and Fibrosis in Cardiovascular Disease
Fibrosis as a hallmark of cardiovascular diseases (lecture)
Pharmacology Honours: Biochemical assays for the measurement of collagen and related proteins (lecture)
PHA3042: Using stem cells for treating fibrosis (lecture)